Headache最新文献

{"title":"Headache in mitochondrial diseases: From migraine to stroke-like episodes.","authors":"Matteo Azzimonti, Samuel Padelli, Dario Ronchi, Simona Sacco, Giacomo Pietro Comi, Stefania Corti","doi":"10.1111/head.70180","DOIUrl":"https://doi.org/10.1111/head.70180","url":null,"abstract":"<p><strong>Objective: </strong>Headaches in primary mitochondrial diseases (PMDs) present distinctive features that warrant differentiation from primary headache disorders. Current knowledge on clinical manifestations, pathophysiology, diagnosis, and treatment is here reviewed.</p><p><strong>Background: </strong>Among the most frequent and disabling symptoms affecting patients with PMDs, headache occurs in approximately 55-71% of individuals. Those with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and related phenotypes are particularly affected. Compared to the general population, migraine prevalence in patients with PMD is up to three- to four-fold higher.</p><p><strong>Methods: </strong>To examine headache across the full spectrum of PMDs, a narrative literature review was conducted. PubMed, Scopus, and Web of Science databases were searched using the terms \"mitochondrial disease,\" \"migraine,\" \"headache,\" \"MELAS,\" and \"stroke-like episodes,\" with no date restrictions. Relevant references from identified articles were also reviewed.</p><p><strong>Results: </strong>In PMDs, migraine with or without aura is the most common type of headache disorder, especially among carriers of the m.3243A>G mutation, the most prevalent pathogenic variant found in MELAS syndrome. Recent data from Mendelian randomization studies have suggested a potential causal link between low mitochondrial DNA copy number and migraine without aura. The clinical characteristics that help differentiate headache in PMDs include protracted or atypical aura, co-occurring neurological and systemic manifestations, temporal relationship with stroke-like episodes, and variable response to conventional therapy. The use of mitochondrial cofactors such as riboflavin, coenzyme Q10, and L-arginine as adjuncts to standard preventive strategies has been supported by only limited evidence.</p><p><strong>Conclusions: </strong>Specialized diagnostic and therapeutic approaches are required for headache management in PMDs, combining mitochondrial-targeted interventions with evidence-based headache treatments. When atypical migraine features are present, particularly prolonged aura or aura occurring with epileptic seizures or encephalopathy, evaluation for underlying mitochondrial disease should be considered.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148445782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of zavegepant use in a tertiary care setting using the Migraine Treatment Optimization Questionnaire-5.","authors":"Eric Dunn, Bradley Ong, Harpreet Kaur, Roman Popov, Claire Sonneborn, Aarushi Suneja","doi":"10.1111/head.70163","DOIUrl":"https://doi.org/10.1111/head.70163","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives/background: &lt;/strong&gt;The introduction of calcitonin gene-related peptide antagonists has transformed migraine care. Zavegepant, a third-generation intranasal gepant, offers a nonoral treatment option for acute migraine. Although clinical trials support its efficacy and safety, real-world data are limited. This study reports patient-reported outcomes of zavegepant at a tertiary care center using the Migraine Treatment Optimization Questionnaire-5 (MTOQ-5) and additional survey questions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this single-center, descriptive, cross-sectional survey study of a retrospectively identified real-world cohort, data were collected from patients prescribed 10 mg intranasal zavegepant at the Cleveland Clinic between July 1, 2023, and December 31, 2024. Surveys were administered from January 2025 to March 2025. Eligible patients completed the MTOQ-5 and additional questions assessing dosage frequency, pain freedom, freedom from the most bothersome symptom, adverse events, and willingness to reuse zavegepant. Demographics including race, ethnicity, sex, age, body mass index, monthly migraine days, headache-free days, and number of preventive and rescue therapies prescribed prior to zavegepant use were also recorded. Of 99 patients surveyed, 60 responded and met inclusion criteria and were included in the analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 60 included patients who used at least two doses, 27 of 60 (45%) patients reported pain freedom within 2 h of most attacks half the time or more, 17 of 60 (28%) reported less than half the time, and 16 of 60 (27%) reported never achieving pain freedom within 2 h. After zavegepant administration, 38 of 60 (63%) patients reported pain freedom within 2 h, and 10 of 60 (17%) patients reported pain freedom within 30 min of use. One dose of zavegepant relieving headache for at least 24 h was reported half the time or more in 26 of 60 (43%) patients. Following zavegepant use, 36 of 60 patients (60%) reported being able to return to normal activities half the time or more, and 43 of 60 (72%) felt comfortable planning daily activities half the time or more with zavegepant. Zavegepant was well-tolerated half the time or more in 41 of 60 (68%) patients. Dysgeusia was the most common adverse event reported. Overall, 43 of 60 (72%) patients would use zavegepant again.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This study represents the first retrospective, real-world, patient-reported outcome study on the use of zavegepant using the validated MTOQ-5. These findings suggest that intranasal zavegepant may be a useful acute migraine treatment option in clinical practice, with patient-reported improvement in pain, most bothersome symptom, function, tolerability, and willingness to reuse. However, the descriptive single-arm design and exclusion of single dose or nonusers limit interpretation and preclude comparative conclusions. Further real-world follow up with larger sample sizes is w","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biochemical profiling and symptomatology of androgen deficiency in males with cluster headache: A prospective case-control study.","authors":"Willemijn C Naber, Roemer B Brandt, Mariël Leon Morales-Grooters, Ronald van der Wal, Sjoerd A A van den Berg, Jelle J Goeman, Antoinette Maassen van den Brink, Rolf Fronczek","doi":"10.1111/head.70174","DOIUrl":"https://doi.org/10.1111/head.70174","url":null,"abstract":"<p><strong>Objectives/background: </strong>Cluster headache (CH) has historically been considered a male-dominated disorder, suggesting a role for androgens in its pathophysiology. We aimed to evaluate hormone profiles and symptoms of androgen deficiency in CH.</p><p><strong>Methods: </strong>In this prospective, matched case-control study with a nested repeated-measures component, fasted morning blood samples were collected in 30 males with chronic CH (CCH), 33 males with episodic CH (ECH; both during episode and remission), and in 30 age-matched male headache-free controls (HCs). Surveys assessing symptoms of androgen deficiency (Quantitative Androgen Deficiency of Aging Males [QADAM], Aging Males' Symptoms [AMS]) were collected simultaneously. Steroid hormone profiles were compared among groups. The primary outcome was total testosterone (tT) including biochemical hypogonadism (tT ≤ 10.5). Secondary outcomes were hormonal pathways and individual hormones. Data were collected between October 2022 and April 2025.</p><p><strong>Results: </strong>Biochemical hypogonadism was observed in 20% of participants with CCH (n = 6), in 9% with ECH (n = 3), and in 7% of HCs (n = 2). None of the HCs had severe hypogonadism, in contrast to those with CH (CCH, n = 3/6; ECH, n = 1/3). AMS and QADAM scores indicated more symptoms of androgen deficiency in participants with hypogonadism, in ECH (AMS: B = 9.59 [95% CI = 5.69-13.50], p < 0.001; QADAM: B = -5.25 [95% CI = -7.39 to -3.11], p < 0.001) and CCH (AMS: B = 8.78 [95% CI = 4.45-13.12], p < 0.001; QADAM: B = -4.59 [95% CI = -6.97 to -2.22], p < 0.001) compared to HCs. In the unadjusted model, we observed a lower, albeit non-statistically significant, mean tT in participants with CCH versus HCs (CCH: B = -2.35 nmol/L [95% CI = -4.79 to 0.09], p = 0.059). In the adjusted model, the differences attenuated, suggesting a strong effect of body mass index and age on the mean tT (CCH: B = -0.93 nmol/L [95% CI = -3.81 to 1.95], p = 0.524; ECH: B = 0.55 nmol/L [95% CI = -2.05 to 3.15], p = 0.674). Measures of hormonal pathways and individual hormones did not differ among groups.</p><p><strong>Conclusion: </strong>Biochemical hypogonadism was observed in one out of five males with CCH versus one out of 20 in the ECH and HCs. Apart from one case, gonadotrophin concentrations were not increased, suggesting a central origin. In the crude data we observed a lower, albeit non-statistically significant, mean tT in males with CCH, but this appeared to be mainly driven by body mass index and age, because it attenuated after correction. Clinical symptoms of androgen deficiency were more prevalent in CH compared to HCs, independent of hypogonadism. Physicians should be aware of potential increased risk and symptoms of (central) hypogonadism in CCH. Further investigation should explore shared underlying mechanisms and testosterone supplementation in CH.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Did the link between anosmia and migraine exist before the COVID-19 pandemic? A population-based cohort study.","authors":"Samuel L Kaefer, Vijay R Ramakrishnan, Jae Hoon Cho","doi":"10.1111/head.70135","DOIUrl":"10.1111/head.70135","url":null,"abstract":"<p><strong>Objectives/background: </strong>The purpose of this study was to investigate the connection between anosmia and migraine. Anosmia and migraine are both disorders that can significantly impact quality of life. Olfaction and headache are clinically associated and share biological connections through interactions between the olfactory and trigeminal sensory systems. The COVID-19 pandemic brought increased attention to anosmia and its neurological implications, including headache. However, despite this renewed interest, epidemiological studies examining the association between anosmia and migraine independent of COVID-19 remain limited.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using data from Korea's National Health Insurance claims database. The study population (n = 3,435,193) consisted of individuals aged ≥20 years who were randomly selected from participants in the 2009 national health screening program. Participants were classified into two groups: the anosmia group (n = 8270), which included individuals diagnosed with anosmia between 2006 and 2008, and a control group (n = 3,426,923) drawn from remaining participants. Both groups were followed from 2011 to 2020 to assess the incidence of migraine.</p><p><strong>Results: </strong>The incidence rate of migraine was higher in the anosmia group (21.85 per 1000 person-years) than in the control group (16.47 per 1000 person-years). After adjusting for multiple covariates, the risk of developing migraine remained significantly elevated in the anosmia group compared with the control group (adjusted hazard ratio=1.19, 95% confidence interval=1.13-1.25).</p><p><strong>Conclusion: </strong>This National cohort study provides insight into the increased incidence of migraine disorder in those with a prior anosmia diagnosis even prior to the COVID-19 pandemic. Additional research is needed to understand mechanisms responsible for this connection between the olfactory and trigeminal systems in neurologic disease.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1587-1596"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148211111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroretinography and pupillary response in migraine.","authors":"Carson C Smith, Shane F H Trivitt, Matthew J Cummings, Amber M Thaxton, Laura Van Key, Caitlin Laycox, Michael A Crognale, Sarah M Haigh","doi":"10.1111/head.70104","DOIUrl":"10.1111/head.70104","url":null,"abstract":"<p><strong>Objective: </strong>To compare rod, cone, and retinal ganglion function with pupillary response in the same migraine and headache-free individuals.</p><p><strong>Background: </strong>Migraine is associated with a sensitivity to the visual environment, including light, stripes, and color, but the biological causes are still heavily debated. One of the potential sources of this sensitivity is abnormal functioning in the retina. Typically, electroretinography (ERG) assessments require dilated pupils to achieve the desired retinal illuminance. However, abnormal pupillary functioning has been linked with migraine, and so artificially dilating the pupil may obscure the effects of migraine on retinal activity.</p><p><strong>Methods: </strong>Here, we compared rod, cone, and the photopic negative-response (to assess retinal ganglion functioning) ERG activity using the RETeval that delivered standard International Society for Clinical Electrophysiology of Vision protocols in 35 individuals with migraine and 25 headache-free individuals. To avoid dilating the pupils, the luminance of the stimuli was continuously adjusted for pupil diameter to hold retinal illumination constant. This allowed for pupil diameter to be measured simultaneously.</p><p><strong>Results: </strong>ERG response amplitudes and timings were similar across migraine and headache-free groups for all protocols, except for a smaller a-wave amplitude in the migraine group in response to the light-adapted slow light flashes. We also found larger pupil diameters in the migraine group, particularly for the dark-adapted protocols, and larger pupils correlated with faster ERG responses to the light-adapted flicker.</p><p><strong>Conclusions: </strong>Together, this suggests that pupil functioning is abnormal in migraine, particularly under specific lighting conditions, and may be linked to a hyper-response to uncomfortable flicker in migraine.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1514-1524"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suzetrigine as a novel treatment for headache disorders: A case series.","authors":"Molly Fensterwald, Jordan Johnson, Angel Moreno, Shawn Conger-Love, Charles Flippen, Chelsea Hesterman, Mollie Johnston, Joshua Kamins, Karla Minota, Peony Pak, Salman Hashim, Thanh-Liem Huynh-Tran, Noelle Kobayashi, Bradley Shane, Andrew Charles, Sinifunanya Nwaobi","doi":"10.1111/head.70147","DOIUrl":"10.1111/head.70147","url":null,"abstract":"<p><p>Suzetrigine is a selective voltage-gated sodium channel blocker that was recently approved by the US Food and Drug Administration for the treatment of acute pain. We retrospectively evaluated the efficacy and tolerability of suzetrigine for the treatment of different headache disorders in patients refractory to standard treatments in an academic headache center. These patients had a variety of headache and facial pain diagnoses, including chronic migraine, medication-overuse headache, trigeminal autonomic cephalalgias, nummular headache, occipital neuralgia, and persistent idiopathic facial pain. Some did not clearly meet any diagnostic criteria. The treatment was generally well tolerated, and most patients reported improvement as measured by patient global impression of change. Suzetrigine is a promising new therapeutic approach that warrants further study for the treatment of headache disorders.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1644-1649"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13326962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148175752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroimaging biomarkers in migraine with aura mimicking stroke: A qualitative and quantitative analysis of perfusion CT alterations.","authors":"Lucía Gómez Martín de la Escalera, Santiago Trillo, Antonio Barbosa Del Olmo, Carmen De Benavides Bernaldo de Queirós, Esther Valiente, Ana Beatriz Gago-Veiga, Cristina Sanabria-Gago, Florentino Nombela, Alicia Gonzalez-Martinez","doi":"10.1111/head.70126","DOIUrl":"10.1111/head.70126","url":null,"abstract":"<p><strong>Objective: </strong>Our main goal was to describe the clinical, analytical, and neuroimaging characteristics of a large series of patients with migraine with aura (MA) as stroke mimic (SM). As secondary goals, we evaluated factors associated with perfusion computed tomography (PCT) alterations in MA.</p><p><strong>Background: </strong>MA is a frequent SM in the acute setting. Increasing our knowledge and awareness of the clinical and radiological characteristics that may occur in the context of a MA as SM may improve diagnosis and reduce unnecessary treatments such as intravenous thrombolysis.</p><p><strong>Methods: </strong>We conducted a retrospective observational cross-sectional study including patients with a final diagnosis of MA who were evaluated at a tertiary hospital and stroke center under the stroke code (SC) protocol activation -focal neurological symptoms occurring within 24 h- between January 1, 2015, and January 31, 2025. Demographic variables (age, sex), clinical features (history of migraine, vascular risk factors, aura type), and biochemical markers (potassium, glucose, and creatinine levels) were collected. Moreover, we explored factors associated with PCT alterations in MA.</p><p><strong>Results: </strong>Among 5513 SC, 68 (1%) were MA, with mean age of 42 (SD: 12.1) years old, 46/68 (68%) females. The most frequent aura symptom was sensory (67%). PCT alterations were found in 15/68 (22%), with a hypoperfusion pattern mainly unilateral, corresponding to a non-vascular territory. The RAPID automatic software was available in 9/15 (60%) patients. Of these, all patients showed T_max > 4 s elevation, and one patient also presented T_max > 6 s elevation. The automatic software analysis identified PCT alterations in five patients that did not show alterations in the qualitative analysis. Male sex (p = 0.003) and aphasic aura (p = 0.004) were associated with PCT alterations in patients with MA.</p><p><strong>Conclusion: </strong>MA as SM forms 1% of SC activation. Automatic RAPID software analysis may help identify PCT alterations that cannot be detected by qualitative analysis. Male sex and aphasia are associated with PCT alterations in MA, which may improve diagnosis in the acute setting.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1607-1616"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13326979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148211137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Joint Special Issue: Clinical Otolaryngology and Headache.","authors":"James R Tysome, Amy A Gelfand","doi":"10.1111/head.70157","DOIUrl":"10.1111/head.70157","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1443-1444"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of real-world acute prescription migraine therapy outcomes: Insights from the HeAD-US study.","authors":"Devin Teichrow, Babak Khorsand, Kristina M Fanning, Alexandre Urani, François Cadiou, Richard B Lipton, Ali Ezzati","doi":"10.1111/head.70113","DOIUrl":"10.1111/head.70113","url":null,"abstract":"<p><strong>Background: </strong>Triptans have long served as the primary acute migraine treatment, whereas gepants represent a newer, non-vasoconstrictive alternative. Although clinical trials have explored efficacy within each class, head-to-head studies are lacking, and real-world data on optimal treatment response and patient-level predictors of outcomes remain limited. We leverage cross-sectional data from the Headache Assessment via Digital Platform in United States study to conduct real-world comparisons of triptans and gepants for 2-h pain freedom (2hPF) and 24-h pain relief (24hPR), and to identify demographic, clinical, and treatment-related predictors of these outcomes.</p><p><strong>Methods: </strong>Head-US is a survey conducted between September and December of 2023 among users of the Migraine Buddy application (Aptar, Crystal Lake, IL). Eligible participants completed the survey, met ICHD-3 criteria for migraine, and reported using acute monotherapy with gepants or a triptan. Primary outcomes, 2hPF and 24hPR posttreatment, were assessed using the Migraine Treatment Optimization Questionnaire-6 item. Potential predictors included demographic factors, clinical measures, and treatment-related factors.</p><p><strong>Results: </strong>Among 1570 eligible respondents, 567 used gepants and 1003 used a triptan. Mean age was 43.35 years (standard deviation = 13.04), and 91.2% were female. Gepant users demonstrated 36% higher odds of achieving 24hPR compared to triptan users (adjusted odds ratio = 1.36, 95% confidence interval: 1.09-1.71), although there were no significant differences the 2hPF outcome. Reduced odds of adequate 2hPF were associated with higher migraine symptom severity, high-frequency episodic migraine, chronic migraine, severe pain intensity, and severe migraine disability. Odds of achieving 24hPR were reduced in those with higher attack frequency, severe migraine disability, and preventive medication use. Predictors of treatment response were similar in the pooled sample and in those using gepants and in those using triptans.</p><p><strong>Conclusion: </strong>In this large, real-world cohort, triptans and gepants did not significantly differ for 2hPF, but gepants demonstrated a significant advantage for 24hPR. Clinical features such as symptom severity, headache frequency, disability, and comorbid treatment burden were important predictors of treatment response. These findings support the need for larger, head-to-head clinical trials definitively comparing these medication classes for migraine management and may inform personalized selection of acute migraine therapies in clinical practice.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1537-1547"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Memoriam-Doctor J. Keith Campbell.","authors":"David J Capobianco, Christine Lay, Jerry W Swanson","doi":"10.1111/head.70140","DOIUrl":"https://doi.org/10.1111/head.70140","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":"66 7","pages":"1456-1457"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}